Search for content, post, videos

Gedea Biotech awarded 3 million SEK

The company has been awarded a grant from the Swedish innovation programs, SWElife and MedTech4Health in a collaboration with Danderyd hospital, Huddinge hospital and Karolinska Institute.

The grant will fund a further clinical trial of its antibiotic free treatment pHyph for the treatment of vulvovaginal candida infections (VVC). The new study, involving 26 patients with VVC to be recruited at four clinics in Sweden, will also analyze the impact the treatment has on the vaginal microbiome which is believed to play a key role in how pHyph treats and prevents recurrence of vaginal infections. Results are expected during the autumn 2023.

“We are delighted to receive this grant from SWElife and MedTech4Health, an investment that is particularly welcome given that women’s health is a neglected area,” says Annette Säfholm, CEO of Gedea Biotech. “The study, which aims to confirm the safety and efficacy of pHyph in the treatment of vulvovaginal candidiasis (VVC), also focuses on analyzing how the vaginal microbiome – believed to play a key role in preventing recurrence – is affected by the treatment.”

Photo of Annette Säfholm: Gedea